Format

Send to

Choose Destination
Cancer Lett. 2015 May 1;360(2):245-56. doi: 10.1016/j.canlet.2015.02.031. Epub 2015 Feb 16.

Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.

Author information

1
Felsenstein Medical Research Center, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Israel.
2
Department of Cell and Developmental Biology, Sackler School of Medicine, Tel Aviv University, Israel.
3
Bioinformatics Unit, Faculty of Life Sciences, Tel Aviv University, Israel.
4
Department of Pediatric Hematology-Oncology, Safra Children's Hospital, Tel-Hashomer, Israel.
5
Felsenstein Medical Research Center, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Israel; Institute of Hematology, Davidoff Cancer Center, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Israel.
6
Institute of Hematology, Assuta Medical Center, Tel-Aviv, Israel.
7
Felsenstein Medical Research Center, Beilinson Hospital, Sackler School of Medicine, Tel Aviv University, Israel. Electronic address: galitg@clalit.org.il.

Abstract

MicroRNAs (miRNAs) are small noncoding RNAs that participate in many biological processes by posttranscriptionally regulating gene expression. Dysregulation of miRNA expression has been shown to be typical of many neoplasms. Chronic myeloid leukemia (CML) is a disorder of hematopoietic stem cells carrying the Philadelphia (Ph) chromosome and an oncogenic BCR-ABL tyrosine kinase fusion gene. While the development of tyrosine kinase inhibitors (TKIs) like imatinib has revolutionized treatment of CML, it has become increasingly clear in recent years that TKI treatment alone will not be curative in many cases. Thus, further dissection of the regulatory networks that drive BCR-ABL-induced malignant transformation may help to identify other novel therapeutic approaches that complement TKI treatment. In this study we demonstrate that the expression of miR-424 is markedly low in CML cell lines and patient samples at time of diagnosis. With the aid of bioinformatics analysis we revealed a conserved target site for miR-424 in the 3'-untranslated region (UTR) of the ABL gene. Via luciferase assays, we showed that miR-424 directly targets BCR-ABL. Overexpression of miR-424 was shown to suppress proliferation and induce apoptosis of K562 cells as well as sensitize these cells to imatinib treatment. These findings strongly suggest that miR-424 acts as a tumor suppressor by downregulating BCR-ABL expression. Up-regulation of miR-424 in CML cells may therefore have a therapeutic effect against this disease.

KEYWORDS:

Apoptosis; BCR–ABL; CML; Imatinib; miR-424

PMID:
25697481
DOI:
10.1016/j.canlet.2015.02.031
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center